Home » Stocks » ABMD

Abiomed, Inc. (ABMD)

Stock Price: $268.56 USD 5.85 (2.23%)
Updated May 14, 2021 4:00 PM EDT - Market closed
Market Cap 12.16B
Revenue (ttm) 812.94M
Net Income (ttm) 200.47M
Shares Out 45.20M
EPS (ttm) 4.94
PE Ratio 54.36
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 14
Last Price $268.56
Previous Close $262.71
Change ($) 5.85
Change (%) 2.23%
Day's Open 266.28
Day's Range 261.27 - 272.92
Day's Volume 262,405
52-Week Range 188.37 - 387.40

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

ABMD, CLMT, FLMN, GRUB, and IHG have been added to the Zacks Rank #5 (Strong Sell) List on May 4, 2021

Other stocks mentioned: CLMT, FLMN, GRUB, IHG
1 week ago - Zacks Investment Research

Despite record revenue for its latest quarter, the medical device maker's shares sank 8% following its earnings release. But its next stage of growth is coming.

1 week ago - The Motley Fool

People will be getting back to their regular routines when it comes to medical and dental care.

Other stocks mentioned: ALGN
1 week ago - The Motley Fool

ABIOMED's (ABMD) international and U.S. Impella revenues improve in Q4.

2 weeks ago - Zacks Investment Research

Abiomed (ABMD) delivered earnings and revenue surprises of 12.73% and 4.72%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

2 weeks ago - Zacks Investment Research

DANVERS, Mass.--(BUSINESS WIRE)--Abiomed announces record revenue of $241 million , up 17% year over year, with 26.0% operating margin.

2 weeks ago - Business Wire

DANVERS, Mass.--(BUSINESS WIRE)--Dr. Paula Johnson joins the Abiomed Board of Directors

2 weeks ago - Business Wire

Strong momentum of ABIOMED's (ABMD) Impella product line, both in Europe and Japan, is expected to have continued in the fiscal fourth quarter as well.

3 weeks ago - Zacks Investment Research

Abiomed (ABMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 weeks ago - Zacks Investment Research

DANVERS, Mass.--(BUSINESS WIRE)--Abiomed (NASDAQ:ABMD) announced today that the first patient has been enrolled in PROTECT IV, a large, prospective, multi-center randomized controlled trial (RCT) that i...

1 month ago - Business Wire

The best is yet to come for each of these companies.

Other stocks mentioned: ISRG, PFE
1 month ago - The Motley Fool

DANVERS, Mass.--(BUSINESS WIRE)--Abiomed announces that on Thursday, April 29, 2021 the Company will release financial results for the fourth quarter of fiscal 2021.

1 month ago - Business Wire

I've been waiting to buy these stocks at a better price. Now might just be the time.

Other stocks mentioned: STAA, TDOC
1 month ago - The Motley Fool

Which healthcare company is a better play for the next decade?

Other stocks mentioned: GH
1 month ago - The Motley Fool

3 Top Medical Instruments Stocks to Beat COVID-19 Resurgence Crisis

Other stocks mentioned: HOLX, IDXX, ISRG, NTUS, TMO
1 month ago - Zacks Investment Research

There are long-term implications to the coronavirus pandemic that the market is not appreciating.

Other stocks mentioned: AAPL, AMZN, CVX, GILD, JNJ, MDT, MRNA ...
1 month ago - The Motley Fool

CMD vs. ABMD: Which Stock Is the Better Value Option?

Other stocks mentioned: CMD
2 months ago - Zacks Investment Research

This medical device company has revenue growth, patents, and a bright outlook.

2 months ago - The Motley Fool

Abiomed (ABMD) reported earnings 30 days ago. What's next for the stock?

2 months ago - Zacks Investment Research

Investors searching for value opportunities may want to have a look at the three stocks listed below, as they represent equities in companies with high profitability and robust financial conditions. In ...

Other stocks mentioned: DECK, GGG
2 months ago - GuruFocus

DANVERS, Mass.--(BUSINESS WIRE)--Abiomed announces the appointment of Myron Rolle, MD, to the Abiomed Board of Directors.

2 months ago - Business Wire

DANVERS, Mass.--(BUSINESS WIRE)--Abiomed to present at upcoming investor conferences.

2 months ago - Business Wire

The market itself is sitting at lofty valuations, but several S&P 500 stocks are extremely overheated. Consider giving these 10 picks a little time to cool off.

Other stocks mentioned: CMG, FTNT, ILMN, MSCI, RMD, ROL, TER ...
3 months ago - Kiplinger

Investor confidence is high in Abiomed (ABMD) stock, courtesy of its solid prospects.

3 months ago - Zacks Investment Research

It's not a vaccine company, a drugmaker, or a diagnostics company.

3 months ago - The Motley Fool

The study proves that Abiomed's (ABMD) Impella 5.5 with SmartAssist delivers successful clinical and device outcomes.

3 months ago - Zacks Investment Research

DANVERS, Mass.--(BUSINESS WIRE)--Abiomed (NASDAQ: ABMD) announces a large study of 356 patients treated with Impella 5.5 with SmartAssist at 16 U.S. and German centers found a 79% survival rate at expla...

3 months ago - Business Wire

The company released its latest quarterly report.

3 months ago - The Motley Fool

Abiomed, Inc.'s (ABMD) CEO Michael Minogue on Q3 2021 Results - Earnings Call Transcript

3 months ago - Seeking Alpha

ABIOMED's (ABMD) international Impella revenues improve in Q3.

3 months ago - Zacks Investment Research

Abiomed (ABMD) delivered earnings and revenue surprises of 1.74% and 2.81%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

3 months ago - Zacks Investment Research

Shares of Abiomed (NASDAQ:ABMD) were unchanged after the company reported Q3 results. Quarterly Results Earnings per share rose 20.54% year over year to $1.35, which beat the estimate of $1.13.

3 months ago - Benzinga

DANVERS, Mass.--(BUSINESS WIRE)--Abiomed announces Q3 fiscal year 2021 record revenue of $232 million, up 5% year over year with 31% operating margin.

3 months ago - Business Wire

The strong momentum of ABIOMED's (ABMD) Impella product line, both in Europe and Japan, is expected to have continued in the fiscal third quarter as well.

3 months ago - Zacks Investment Research

DANVERS, Mass.--(BUSINESS WIRE)--Abiomed announces the company will release financial results for the third quarter of fiscal 2021 on January 28, 2021.

4 months ago - Business Wire

Due to the persistence of global manufacturing and supply-chain disruptions and a few other hostile externalities, three stocks are likely to register a dull 2021 performance.

Other stocks mentioned: MDRX, PACB
4 months ago - Zacks Investment Research

DANVERS, Mass.--(BUSINESS WIRE)--Abiomed (NASDAQ: ABMD) announces it has surpassed more than 1,000 patents worldwide, with more than 850 additional patents pending. Abiomed's robust intellectual propert...

4 months ago - Business Wire

Abiomed's AAA financials, including a clean balance sheet and world-class margins can justify a premium in its valuation. Discounting Abiomed's future free cash flows, we derive the stock's intrinsic va...

4 months ago - Seeking Alpha

DANVERS, Mass.--(BUSINESS WIRE)--Abiomed to present at the 39th annual J.P. Morgan Healthcare conference.

4 months ago - Business Wire

Abiomed (ABMD) successfully treats first two patients in the world with the help of its Breethe OXY-1 System.

4 months ago - Zacks Investment Research

DANVERS, Mass.--(BUSINESS WIRE)--The first two patients in the world have been treated with the Abiomed Breethe OXY-1 System, including a COVID-19 patient in respiratory failure.

4 months ago - Business Wire

DANVERS, Mass.--(BUSINESS WIRE)--Abiomed (NASDAQ: ABMD) announces the achievement of two milestones in the development of small bore access for the Impella heart pump. The Impella ECP heart pump has com...

5 months ago - Business Wire

Biotech stocks simply can't match these reliable returns.

Other stocks mentioned: DXCM, MDT
5 months ago - The Motley Fool

DANVERS, Mass.--(BUSINESS WIRE)--Abiomed to hold fireside chat at the Stephens Annual Investment Conference 2020.

6 months ago - Business Wire

It depends on whether or not the company's decelerating revenue growth is a symptom of larger problems.

6 months ago - The Motley Fool

DANVERS, Mass.--(BUSINESS WIRE)--Abiomed (NASDAQ: ABMD) announces 1,000 patients have been treated with the Impella 5.5 with SmartAssist heart pump in the first year after the U.S. Food and Drug Adminis...

6 months ago - Business Wire

Revenue bounces back, but growth is still lacking.

6 months ago - The Motley Fool

Abiomed, Inc. (ABMD) CEO Mike Minogue on Q2 2021 Results - Earnings Call Transcript

6 months ago - Seeking Alpha

ABIOMED's (ABMD) international Impella revenues improved in Q2.

6 months ago - Zacks Investment Research

Abiomed (ABMD) delivered earnings and revenue surprises of 16.09% and 4.16%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

About ABMD

Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; and Impella CP, a device used by interventional cardiologists to support patients in the cath lab and cardiac surgeons in the heart surgery suite. It also provides Impella 5.0 and Impella LD, which... [Read more...]

Industry
Medical Devices
IPO Date
Jul 29, 1987
CEO
Michael Minogue
Country
United States
Stock Exchange
NASDAQ
Ticker Symbol
ABMD
Full Company Profile

Financial Performance

In 2019, Abiomed's revenue was $840.88 million, an increase of 9.29% compared to the previous year's $769.43 million. Earnings were $203.01 million, a decrease of -21.62%.

Financial Statements

Analyst Forecasts

According to 9 analysts, the average rating for Abiomed stock is "Buy." The 12-month stock price forecast is 374.00, which is an increase of 39.26% from the latest price.

Price Target
$374.00
(39.26% upside)
Analyst Consensus: Buy